XFOR PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

XFOR ▼ -9.36% at T+20d

NEUTRAL call ✗ call lost -9.36% · α vs SPY -12.14% · entry $4.38 → $3.97

Next anchor: T+60d in 7w

Currently $3.85 · -12.10% from $4.38 entry

Entry anchored
May 5, 03:59 PM ET
via Databento tick

T+1d

-2.05%

call -2.05% · α -1.72%

$4.29

settled 5w ago

T+5d

-0.91%

call -0.91% · α -2.04%

$4.34

settled 28d ago

T+20d

-9.36%

call -9.36% · α -12.14%

$3.97

settled 6d ago

T+60d

—

call — · α —

—

in 7w

Price Chart

Loading chart...

Executive Summary

X4 Pharmaceuticals reported Q1 2026 revenue of $2.7M (vs $3.2M consensus) and GAAP EPS of -$0.16 (vs consensus -$0.20, a beat of 20%). The revenue miss was driven by the absence of the prior-year $27.9M Norgine license fee, while product revenue grew to $2.5M from $0.9M. The company reiterated its Phase 3 4WARD trial enrollment timeline and cash runway through 2028, but the revenue decline and net loss swing from prior-year profit are material negatives.

Actionable Insight

The revenue miss is largely structural (one-time license fee lapsing), but the net loss swing and reliance on a single Phase 3 readout create binary risk. Monitor 4WARD enrollment updates and any Norgine milestone announcements. Cash runway through 2028 removes near-term financing risk.

Key Facts

Q1 2026 total revenue $2.7M vs $28.8M in Q1 2025, a 90.6% decline due to absence of $27.9M Norgine license revenue
GAAP net loss of $(20.2)M or $(0.16)/share vs net income of $0.3M or $0.04/share in Q1 2025
Product revenue (XOLREMDI) grew to $2.5M from $0.9M year-over-year, a 162% increase
Cash position $233.7M as of March 31, 2026, providing runway through 2028
European Commission approved XOLREMDI for WHIM syndrome; Norgine to lead commercialization with up to €226M in milestones plus double-digit royalties
Phase 3 4WARD chronic neutropenia trial on track to complete enrollment by end of Q3 2026

Financial Impact

Revenue decline of $26.1M YoY driven by one-time license fee; net loss swing of $20.5M; product revenue growth of $1.5M partially offsetting

revenuenet incomeepsproduct revenue

Risk Factors

Phase 3 4WARD trial failure would eliminate pipeline value and likely require restructuring
Product revenue from XOLREMDI remains small ($2.5M/quarter) and may not offset operating burn
Dependence on Norgine for European commercialization; milestone timing uncertain

Market Snapshot

Exchange

Nasdaq

Sector

Biological Products, (No Diagnostic Substances)

Analyst Consensus

89% bullish (9 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3288685

6 reports for XFOR

T+1T+5T+20T+60

Filters

Reports for XFOR — sortable, filterable
	Type				Now
May 18, 2026 22d ago	EFFECT NEUTRAL ★ 4/10	$3.68 $4.00	▲ +8.70%	▲ +7.08%	$3.85 (+4.62%)
May 12, 2026 28d ago	144 NEUTRAL ★ 2/10	$4.23 $3.64	▼ −13.95%	▼ −12.79%	$3.85 (−8.98%)
May 12, 2026 28d ago	8-K NEUTRAL ★ 2/10	$4.23 $3.64	▼ −13.95%	▼ −12.79%	$3.85 (−8.98%)
May 6, 2026 4w ago	Press Release MIXED ★ 6/10	$4.38 $4.34	▼ −0.91%	▼ −2.04%	$3.85 (−12.10%)
Mar 20, 2026 11w ago	DEFA14A NEUTRAL ★ 2/10	$4.28 $4.04	▼ −5.61%	▼ −3.46%	$3.85 (−10.05%)
Mar 17, 2026 12w ago	Press Release MIXED ★ 6/10	$4.23 $3.82	▼ −9.69%	▼ −7.04%	$3.85 (−8.98%)

US Market Status

Market Closed — Opens Thu (10h 7m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access